Innoforce Pharmaceuticals

About Innoforce Pharmaceuticals

Innoforce is a leading Contract Development and Manufacturing Organization (CDMO) focused on Advanced Therapy Medicinal Products (ATMPs). The company provides a comprehensive range of services from the pre-clinical phase through clinical and commercial phases, specializing in the development and manufacturing of high-quality plasmid DNA, RNA, lipid nanoparticles (LNP), exosomes, viral vectors, and cell therapeutics. Innoforce serves a diverse clientele, including biotech and pharmaceutical companies, by offering tailored solutions that ensure the highest standards of quality and reliability.

Operating in the global market, Innoforce's business model revolves around leveraging its proprietary technologies and extensive expertise to deliver innovative and scalable solutions. The company generates revenue through service contracts, providing end-to-end manufacturing solutions that are customized to meet the specific needs of each client. Innoforce's commitment to protecting intellectual property (IP) is evident through its rigorous policies and procedures, which include assigning separate teams and rooms for each client to prevent information sharing between projects.

Innoforce does not maintain its own product pipeline, allowing it to focus entirely on client success without any conflict of interest. This client-centric approach, combined with its advanced technology platforms, positions Innoforce as a premier partner in the ATMP space.